Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Nimotuzumab> ?p ?o. }
Showing items 1 to 60 of
60
with 100 items per page.
- Nimotuzumab abstract "Nimotuzumab (BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody used to treat squamous cell carcinomas of the head and neck, recurrent or refractory high grade malignant glioma, anaplastic astrocytomas, glioblastomas and diffuse intrinsic pontine glioma. Like cetuximab, nimotuzumab binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. Most monoclonal antibodies are originally created by mouse cells, but this can cause an immune reaction to mouse proteins. Humanised antibodies are made using parts of mouse proteins and parts of human proteins, which causes less of an immune reaction. Nimotuzumab contains 95% human antibody sequences. This reduces adverse effects such as rash, diarrhea and conjunctivitis.[citation needed]".
- Nimotuzumab atcPrefix "L01XC".
- Nimotuzumab casNumber "828933-61-3".
- Nimotuzumab wikiPageExternalLink www.eurofarma.com.br.
- Nimotuzumab wikiPageExternalLink www.innogene-kalbiotech.com.
- Nimotuzumab wikiPageExternalLink www.oncoscienceag.com.
- Nimotuzumab wikiPageExternalLink www.ymbiosciences.com.
- Nimotuzumab wikiPageID "9685912".
- Nimotuzumab wikiPageRevisionID "544703396".
- Nimotuzumab atcPrefix "L01XC".
- Nimotuzumab c "6566".
- Nimotuzumab casNumber "828933".
- Nimotuzumab chemspiderid "NA".
- Nimotuzumab eliminationHalfLife "1094400.0".
- Nimotuzumab h "10082".
- Nimotuzumab hasPhotoCollection Nimotuzumab.
- Nimotuzumab mabType "mab".
- Nimotuzumab molecularWeight "151".
- Nimotuzumab n "1746".
- Nimotuzumab o "2056".
- Nimotuzumab routesOfAdministration "Intravenous".
- Nimotuzumab s "40".
- Nimotuzumab source "zu/o".
- Nimotuzumab target Epidermal_growth_factor_receptor.
- Nimotuzumab type "mab".
- Nimotuzumab verifiedfields "changed".
- Nimotuzumab verifiedrevid "458282858".
- Nimotuzumab subject Category:Monoclonal_antibodies_for_tumors.
- Nimotuzumab type Abstraction100002137.
- Nimotuzumab type Antibody115027189.
- Nimotuzumab type Chemical114806838.
- Nimotuzumab type Compound114818238.
- Nimotuzumab type Macromolecule114944888.
- Nimotuzumab type Material114580897.
- Nimotuzumab type Matter100020827.
- Nimotuzumab type Molecule114682133.
- Nimotuzumab type MonoclonalAntibodiesForTumors.
- Nimotuzumab type MonoclonalAntibody115029781.
- Nimotuzumab type OrganicCompound114727670.
- Nimotuzumab type Part113809207.
- Nimotuzumab type PhysicalEntity100001930.
- Nimotuzumab type Protein114728724.
- Nimotuzumab type Relation100031921.
- Nimotuzumab type Substance100019613.
- Nimotuzumab type Thing100002452.
- Nimotuzumab type Unit109465459.
- Nimotuzumab type Drug.
- Nimotuzumab type DrugProduct.
- Nimotuzumab type FunctionalSubstance.
- Nimotuzumab comment "Nimotuzumab (BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody used to treat squamous cell carcinomas of the head and neck, recurrent or refractory high grade malignant glioma, anaplastic astrocytomas, glioblastomas and diffuse intrinsic pontine glioma.".
- Nimotuzumab label "Nimotuzumab".
- Nimotuzumab label "Nimotuzumab".
- Nimotuzumab label "نيموتوزوماب".
- Nimotuzumab sameAs Nimotuzumab.
- Nimotuzumab sameAs m.02pp30g.
- Nimotuzumab sameAs Q3877039.
- Nimotuzumab sameAs Q3877039.
- Nimotuzumab sameAs Nimotuzumab.
- Nimotuzumab wasDerivedFrom Nimotuzumab?oldid=544703396.
- Nimotuzumab isPrimaryTopicOf Nimotuzumab.